Abstract:The newly synthesized quinoline-benzimidazole hybrids containing two types of triazole-methyl-phenoxy linkers were characterized via NMR and elemental analysis. Additional derivatization was achieved by introducing bromine at the C-2 position of the phenoxy core. These novel hybrids were tested for their effects on the growth of the non-tumor cell line MRC-5 (human fetal lung fibroblasts), leukemia and lymphoma cell lines: Hut78, THP-1 and HL-60, and carcinoma cell lines: HeLa and CaCo-2. The results obtained, presented as the concentration that achieves 50% inhibition of cell growth (IC50 value), show that the compounds tested affect tumor cell growth differently depending on the cell line and the dose applied (IC50 ranged from 0.2 to >100 µM). The quinoline-benzimidazole hybrids tested, including 7-chloro-4-(4-{[4-(5-methoxy-1H-1,3-benzo[d]imidazol-2-yl)phenoxy]methyl}-1H-1,2,3-triazol-1-yl)quinoline 9c, 2-(3-bromo-4-{[1-(7-chloroquinolin-4-yl)-1H-1,2,3-triazol-4-yl]methoxy}phenyl)-N-propyl-1H-benzo[d]imidazol-5-carboximidamide trihydrochloride 10e, 2-{4-[(1-{2-[(7-chloroquinolin-4-yl)amino]ethyl}-1H-1,2,3-triazol-4-yl)methoxy]phenyl}-N-propyl-1H-benzo[d]imidazol-5-carboximidamide trihydrochloride 14e and 2-{3-bromo-4-[(1-{2-[(7-chloroquinolin-4-yl)amino]ethyl}-1H-1,2,3-triazol-4-yl)methoxy]phenyl}-N-propyl-1H-benzo[d]imidazol-5-carboximidamide trihydrochloride 15e, arrested the cell cycle of lymphoma (HuT78) cells. The calculated ADMET properties showed that the synthesized compounds violated at most two of Lipinski's rules, making them potential drug candidates, but mainly for parenteral use due to low gastrointestinal absorption. The quinoline-benzimidazole hybrid 14e, which was shown to be a potent and selective inhibitor of lymphoma cell line growth, obtained the highest binding energy (-140.44 kcal/mol), by docking to the TAO2 kinase domain (PDB: 2GCD).

Discovery of 1H-Benzo[d][1,2,3]triazol-1-yl 3,4,5-Trimethoxybenzoate As a Potential Antiproliferative Agent by Inhibiting Histone Deacetylase.

Bioactive Heterocycles Containing a 3,4,5-Trimethoxyphenyl Fragment Exerting Potent Antiproliferative Activity Through Microtubule Destabilization.

Design and Synthesis of Novel Dehydroepiandrosterone Analogues As Potent Antiproliferative Agents

Synthesis and Evaluation of 2-[2-(phenylthiomethyl)-1h-benzo[d] Imidazol-1-yl)acetohydrazide Derivatives As Antitumor Agents

Design, Synthesis, and Anticancer Activity Evaluation of Hybrids of Azoles and Barbituric Acids.

3d-Qsar And Molecular Docking Studies On Benzotriazoles As Antiproliferative Agents And Histone Deacetylase Inhibitors

New 3-[(4-hydroxy-6-methly-2(1h)-pyridinones)-3-yl]-4-substituted-(1h)1,2,4- Triazole-5-Thiones: Efficient Synthesis, X-Ray Crystallographic Analysis, and Antitumor Activity

Discovery of quinazolinyl-containing benzamides derivatives as novel HDAC1 inhibitors with in vitro and in vivo antitumor activities

Discovery of [1,2,4]triazolo[1,5-a]pyrimidines derivatives as potential anticancer agents

Discovery and optimization of a series of 2-aryl-4-amino-5-(3',4',5'-trimethoxybenzoyl)thiazoles as novel anticancer agents.

Discovery of Novel Indole-1,2,4-triazole Derivatives As Tubulin Polymerization Inhibitors.

Design, Synthesis and Biological Evaluation of [1,2,3]Triazolo[4,5-D] Pyrimidine Derivatives Possessing A Hydrazone Moiety As Antiproliferative Agents

A novel [1,2,4] triazolo [1,5-a] pyrimidine-based phenyl-linked steroid dimer: synthesis and its cytotoxic activity.

Design and synthesis of triazolopyridine derivatives as potent JAK/HDAC dual inhibitors with broad-spectrum antiproliferative activity

Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives containing hydrazone fragment as potent and selective anticancer agents

Novel 1,2,3-Triazole-Containing Quinoline-Benzimidazole Hybrids: Synthesis, Antiproliferative Activity, In Silico ADME Predictions, and Docking

Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives containing benzodioxole as potential anticancer agents.

Discovery of (S)-N-(2-amino-4-fluorophenyl)-4-(1-(3-(4-((dimethylamino)methyl)phenyl)-6-oxopyridazin-1(6h)-yl)ethyl)benzamide As Potent Class I Selective HDAC Inhibitor for Oral Anticancer Drug Candidate.

Discovery of highly potent tubulin polymerization inhibitors: Design, synthesis, and structure-activity relationships of novel 2,7-diaryl-[1,2,4]triazolo[1,5-a]pyrimidines

Electrochemical Synthesis of New Isoxazoles and Triazoles Tethered with Thiouracil Base as Inhibitors of Histone Deacetylases in Human Breast Cancer Cells

Synthesis, Crystal Structure, DFT Studies, Hirshfeld Suface Analysis and Antitumor Activity of 4-(tert-Butyl)-5-(1,2,4-triazole-1-yl)thiazole Derivatives Containing Benzoxazinone